Filana Therapeutics adds biopharma executive Jill Quigley to board
The Austin-based company named Quigley a Class I director as it prepares to begin a Phase 2a study of simufilam in TSC-related epilepsy.
SEC filing
1 story
The Austin-based company named Quigley a Class I director as it prepares to begin a Phase 2a study of simufilam in TSC-related epilepsy.
SEC filing